J Korean Matern Child Health .  2024 Apr;28(2):35-41. 10.21896/jkmch.2024.28.2.35.

Surfactant Therapy in Respiratory Distress Syndrome

• KMID: 2555188
• DOI: http://doi.org/10.21896/jkmch.2024.28.2.35

Abstract

Respiratory distress syndrome (RDS) is the leading cause of neonatal respiratory morbidity and mortality. Advancements in neonatal care, along with extended insurance coverage, have resulted in increased utilization of surfactant replacement therapy (SRT) for RDS. This has contributed to a decrease in neonatal mortality. The primary mode of respiratory support in infants with RDS has dramatically changed over the last decades, transitioning from invasive to noninvasive support. Therefore, less invasive surfactant therapy has emerged as a widely adopted approach for SRT, establishing itself as a standard method in preterm infants’ care. This review addresses pulmonary surfactant, from its discovery to application in newborns with RDS. It also reviews the history of guidelines of SRT and health insurance issues. Future studies should evaluate various emerging noninvasive respiratory support modalities along with SRT for the respiratory management of neonates, given the lack of sufficient evidence regarding these approaches.

Reference

Abdel-Latif ME., Walker E., Osborn DA. Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst Rev. 2024. 1:CD008309.

Avery ME., Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child. 1959. 97(5, Part 1):517–23.

Bae CW., Kim CY., Chung SH., Choi YS. History of pulmonary surfactant replacement therapy for neonatal respiratory distress syndrome in Korea. J Korean Med Sci. 2019. 34:e175.

Bahadue FL., Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2012. 11:CD001456.

Choi HJ., Hahn S., Lee J., Park BJ., Lee SM., Kim HS., Bae CW, et al. Surfactant lavage therapy for meconium aspiration syndrome: a systematic review and meta-analysis. Neonatology. 2012. 101:183–91.

Committee on Fetus and Newborn, American Academy of Pediatrics. Respiratory support in preterm infants at birth. Pediatrics. 2014. 133:171–4.

Dani C., Bertini G., Pezzati M., Cecchi A., Caviglioli C., Rubaltelli FF. Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks’ gestation. Pediatrics. 2004. 113:e560–3.

Dargaville PA., Aiyappan A., Cornelius A., Williams C., De Paoli AG. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch Dis Child Fetal Neonatal Ed. 2011. 96:F243–8.

Dargaville PA., Aiyappan A., De Paoli AG., Dalton RG., Kuschel CA., Kamlin CO, et al. Continuous positive airway pressure failure in preterm infants: incidence, predictors and consequences. Neonatology. 2013. 104:8–14.

El Shahed AI., Dargaville P., Ohlsson A., Soll RF. Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database Syst Rev. 2007. 3:CD002054.

European Exosurf Study Group. Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. Online J Curr Clin Trials. 1992. Doc No 28:[3886 words; 47 paragraphs].

Finer NN., Carlo WA., Walsh MC., Rich W., Gantz MG., Laptook AR, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010. 362:1970–9.

Fuchs H., Lindner W., Leiprecht A., Mendler MR., Hummler HD. Predictors of early nasal CPAP failure and effects of various intubation criteria on the rate of mechanical ventilation in preterm infants of <29 weeks gestational age. Arch Dis Child Fetal Neonatal Ed. 2011. 96:F343–7.

Fujiwara T., Maeta H., Chida S., Morita T., Watabe Y., Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet. 1980. 1:55–9.

Gruenwald P. Surface tension as a factor in the resistance of neonatal lungs to aeration. Am J Obstet Gynecol. 1947. 53:996–1007.

Hallman M., Herting E. Historical perspective on surfactant therapy: transforming hyaline membrane disease to respiratory distress syndrome. Semin Fetal Neonatal Med. 2023. 28:101493.

Hillman N., Jobe AH. Noninvasive strategies for management of respiratory problems in neonates. Neoreviews. 2013. 14:e227–36.

Hong CY., Ahn HS., Young SH. Pediatrics. 12th ed. Seoul (Korea): Mirae N;2020.

Isayama T., Iwami H., McDonald S., Beyene J. Association of noninvasive ventilation strategies with mortality and bronchopulmonary dysplasia among preterm infants: a systematic review and metaanalysis. JAMA. 2016. 316:611–24.

Jeon GW. Surfactant preparations for preterm infants with respiratory distress syndrome: past, present, and future. Korean J Pediatr. 2019. 62:155–61.

Jeon GW., Lee JH., Oh M., Chang YS. Serial short-term outcomes of very-low-birth-weight infants in the Korean Neonatal Network from 2013 to 2020. J Korean Med Sci. 2022. 37:e229.

Kanmaz HG., Erdeve O., Canpolat FE., Mutlu B., Dilmen U. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics. 2013. 131:e502–9.

Kesler H., Lohmeier K., Hoehn T., Kribs A., Peinemann F. Thincatheter surfactant application for respiratory distress syndrome in spontaneously breathing preterm infants: a meta-analysis of randomized clinical trials. Curr Pediatr Rev. 2022. 18:286–300.

Klebermass-Schrehof K., Wald M., Schwindt J., Grill A., Prusa AR., Haiden N, et al. Less invasive surfactant administration in extremely preterm infants: impact on mortality and morbidity. Neonatology. 2013. 103:252–8.

Kolatat T., Aunganon K., Yosthiem P. Airway complications in neonates who received mechanical ventilation. J Med Assoc Thai. 2002. 85(Suppl 2):S455–62.

Kribs A., Pillekamp F., Hünseler C., Vierzig A., Roth B. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age </=27 weeks). Paediatr Anaesth. 2007. 17:364–9.

Ma CC., Ma S. The role of surfactant in respiratory distress syndrome. Open Respir Med J. 2012. 6:44–53.

Morley CJ., Davis PG., Doyle LW., Brion LP., Hascoet JM., Carlin JB. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med. 2008. 358:700–8.

Ng EH., Shah V. Guidelines for surfactant replacement therapy in neonates. Paediatr Child Health. 2021. 26:35–49.

Plavka R., Kopecký P., Sebron V., Leiská A., Svihovec P., Ruffer J, et al. Early versus delayed surfactant administration in extremely premature neonates with respiratory distress syndrome ventilated by high-frequency oscillatory ventilation. Intensive Care Med. 2002. 28:1483–90.

Polin RA., Carlo WA. Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics. 2014. 133:156–63.

Ramaswamy VV., More K., Roehr CC., Bandiya P., Nangia S. Efficacy of noninvasive respiratory support modes for primary respiratory support in preterm neonates with respiratory distress syndrome: Systematic review and network meta-analysis. Pediatr Pulmonol. 2020. 55:2940–63.

Rojas MA., Lozano JM., Rojas MX., Laughon M., Bose CL., Rondon MA, et al. Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial. Pediatrics. 2009. 123:137–42.

Rojas-Reyes MX., Morley CJ., Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2012. 3:CD000510.

Shim GH. Update of minimally invasive surfactant therapy. Korean J Pediatr. 2017. 60:273–81.

Shin JE., Yoon SJ., Lim J., Han J., Eun HS., Park MS, et al. Pulmonary surfactant replacement therapy for respiratory distress syndrome in neonates: a nationwide epidemiological study in Korea. J Korean Med Sci. 2020. 35:e253.

Silveira RC., Panceri C., Munõz NP., Carvalho MB., Fraga AC., Procianoy RS. Less invasive surfactant administration versus intubation-surfactant-extubation in the treatment of neonatal respiratory distress syndrome: a systematic review and meta-analyses. J Pediatr (Rio J). 2024. 100:8–24.

Soll RF., Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2001. 2:CD000510.

Stevens TP., Harrington EW., Blennow M., Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev. 2007. 2007:CD003063.

Sweet DG., Carnielli VP., Greisen G., Hallman M., Klebermass-Schrehof K., Ozek E, et al. European Consensus Guidelines on the management of respiratory distress syndrome: 2022 update. Neonatology. 2023. 120:3–23.

Sweet DG., Carnielli V., Greisen G., Hallman M., Ozek E., Plavka R, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2013 update. Neonatology. 2013. 103:353–68.

Sweet DG., Carnielli V., Greisen G., Hallman M., Ozek E., Te Pas A, et al. European Consensus Guidelines on the management of respiratory distress syndrome-2019 update. Neonatology. 2019. 115:432–50.

Venkatesh V., Ponnusamy V., Anandaraj J., Chaudhary R., Malviya M., Clarke P, et al. Endotracheal intubation in a neonatal population remains associated with a high risk of adverse events. Eur J Pediatr. 2011. 170:223–7.

Verder H., Albertsen P., Ebbesen F., Greisen G., Robertson B., Bertelsen A, et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks’ gestation. Pediatrics. 1999. 103:E24.